GO:0019628 urate catabolic process: Urate Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019628 urate catabolic process describes the chemical reactions and pathways that break down urate, the anion of uric acid (2,6,8-trioxypurine).
• Urate is the end product of purine metabolism in humans because the gene encoding urate oxidase (uricase) is non-functional, so urate catabolism in humans depends mainly on renal and extra-renal excretion rather than enzymatic degradation.
• Urate transport proteins such as URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2 and OAT1/OAT3 determine how much urate is reabsorbed or excreted, and their dysfunction alters urate catabolic flux and serum urate levels.
• Decreased extra-renal urate excretion, especially through the gut, is a common cause of hyperuricemia and contributes to gout.
• Hyperuricemia and gout are the main human diseases linked to impaired urate catabolic process, and therapeutic strategies aim to increase urate elimination or lower urate production.
• CRISPR-based knockout, point-mutation, knock-in and overexpression cell models allow researchers to test whether candidate urate transporters or metabolic enzymes causally regulate urate catabolic process.
Description
GO:0019628 urate catabolic process is a Gene Ontology biological process term defined as the chemical reactions and pathways resulting in the breakdown of urate, the anion of uric acid, 2,6,8-trioxypurine. Urate is the final oxidation product of purine metabolism in humans and great apes, and its concentration in blood and tissues is tightly linked to renal and intestinal transport systems. Because humans lack a functional urate oxidase enzyme, the catabolic process is largely represented by transport-mediated elimination and downstream oxidation or microbial degradation rather than by a single enzymatic step. Understanding this process is therefore central to nephrology, rheumatology and metabolic disease research.
urate catabolic process At A Glance
| GO ID | GO:0019628 |
|---|---|
| GO term | urate catabolic process |
| Ontology | biological_process |
| Synonym | urate breakdown; urate catabolism; urate degradation; uric acid catabolic process |
| Definition | The chemical reactions and pathways resulting in the breakdown of urate, the anion of uric acid, 2,6,8-trioxypurine. |
| Major function | Breakdown and elimination of urate, the end product of purine metabolism in humans |
| Key transporters | URAT1 (SLC22A12), GLUT9 (SLC2A9), ABCG2, OAT1 (SLC22A6), OAT3 (SLC22A8) |
| Associated diseases | Hyperuricemia, gout, renal hypouricemia, uric acid nephrolithiasis |
| Research relevance | Target for urate-lowering therapies and for CRISPR-based functional validation of urate transporters |
What Is GO:0019628?
In practical terms, GO:0019628 urate catabolic process covers all biochemical reactions and pathways that convert urate into less oxidized or more excretable products. The QuickGO definition states that it is the chemical reactions and pathways resulting in the breakdown of urate, the anion of uric acid, 2,6,8-trioxypurine. This includes enzymatic oxidation of urate by urate oxidase in organisms that retain a functional enzyme, as well as transport and metabolic steps that remove urate from circulation and tissues in humans. The term is a biological process and is distinct from urate biosynthetic or purine salvage terms.
Why Is urate catabolic process Important in Cell Biology?
Urate catabolic process matters because urate is the terminal purine metabolite in humans and its accumulation causes hyperuricemia, gout and uric acid kidney stones. Genetic and physiological studies show that renal and extra-renal urate excretion, not enzymatic degradation, is the dominant route of urate removal in humans, making transport proteins central to this process. Consequently, understanding GO:0019628 informs drug development, dietary intervention and CRISPR-based disease modeling for metabolic and renal disorders.
• Urate is the end product of purine metabolism in humans, so its catabolic process determines serum urate levels.
• Impaired urate catabolic process and excretion cause hyperuricemia, a risk factor for gout.
• Renal urate transport proteins such as URAT1 and GLUT9 are directly involved in urate handling and catabolic flux.
• Extra-renal, especially intestinal, urate excretion is a common determinant of hyperuricemia.
• Gout is a chronic inflammatory arthritis driven by urate crystal deposition when urate catabolic process is insufficient.
• Therapies for hyperuricemia target urate production or excretion, highlighting the clinical importance of this process.
• Gut microbiome and metabolome reprogramming can ameliorate hyperuricemia, linking microbial urate catabolism to host urate balance.
• CRISPR screens and knockout models can identify causal genes in urate catabolic process.
• Urate transporters are evolving drug targets for urate-lowering therapy.
• Understanding urate catabolic process helps explain species differences in urate oxidase activity and urate handling.
What Happens During urate catabolic process?
Urate production and the absence of urate oxidase in humans
In simple terms: Humans make urate but cannot break it down efficiently because the enzyme that does this job is inactive.
Urate is generated as the final oxidation product of purine metabolism. In most mammals, urate oxidase (uricase) further oxidizes urate to allantoin, but in humans and great apes the uricase gene is non-functional, so urate becomes the end product. This loss of enzymatic urate catabolism makes humans dependent on excretion pathways to maintain urate balance.
Renal urate handling and reabsorption
In simple terms: The kidney filters urate and then reabsorbs most of it, so small changes in transporters can strongly affect urate levels.
Renal urate transport involves apical and basolateral transporters. URAT1 (SLC22A12) mediates urate reabsorption in exchange for organic anions, while GLUT9 (SLC2A9) facilitates urate efflux on the basolateral side. OAT1 and OAT3 contribute to urate secretion and are part of the evolving field of urate transporters. Dysfunction of these proteins alters net urate excretion and can cause hyperuricemia or renal hypouricemia.
Extra-renal and intestinal urate excretion
In simple terms: The gut also removes urate, and when this route fails, urate builds up in the blood.
Decreased extra-renal urate excretion, particularly through the intestine, is a common cause of hyperuricemia. ABCG2 is a key ATP-binding cassette transporter involved in intestinal and renal urate efflux, and its variants influence gout risk. This extra-renal component is now recognized as a major determinant of urate catabolic process in humans.
Microbial and dietary modulation of urate catabolism
In simple terms: Gut bacteria and diet can change how much urate is broken down or removed.
Sulforaphane-driven reprogramming of the gut microbiome and metabolome ameliorates hyperuricemia progression, indicating that microbial metabolism can influence host urate catabolic process. Dietary and pharmacological interventions that alter urate production or excretion are therefore relevant to this GO term.
Pharmacological targeting of urate catabolic process
In simple terms: Drugs can lower urate by blocking its production or increasing its removal.
The treatment of hyperuricemia includes xanthine oxidase inhibitors that reduce urate production and uricosuric agents that increase renal urate excretion. These therapies act on the same physiological axis described by GO:0019628 and are used to prevent gout flares and urate crystal deposition.
Key Genes Involved in GO:0019628 urate catabolic process
The following genes and proteins are experimentally and clinically linked to urate catabolic process, urate transport and hyperuricemia.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A12 (URAT1) | Apical urate reabsorption in kidney | Target for uricosuric drugs; loss-of-function causes renal hypouricemia |
| SLC2A9 (GLUT9) | Basolateral urate efflux in kidney and intestine | GWAS locus for serum urate and gout |
| ABCG2 | ATP-binding cassette urate efflux transporter | Intestinal and renal urate excretion; gout risk locus |
| SLC22A6 (OAT1) | Renal organic anion transporter involved in urate secretion | Drug-transporter interaction studies |
| SLC22A8 (OAT3) | Renal organic anion transporter involved in urate secretion | Urate transport and pharmacokinetics |
| SLC17A1 (NPT1) | Urate transporter in kidney | Candidate gene for urate handling |
| SLC17A3 (NPT4) | Urate efflux transporter | Urate excretion and hyperuricemia |
| SLC16A9 (MCT9) | Monocarboxylate transporter linked to urate | GWAS association with urate levels |
| SLC22A11 (OAT4) | Apical urate transporter | Urate reabsorption and drug interactions |
| PDZK1 | Scaffold protein for urate transporters | Regulates URAT1 and other transporters |
| XDH (xanthine dehydrogenase/oxidase) | Produces urate from xanthine | Drug target for urate-lowering therapy |
| URAT1/SLC22A12 variants | Altered urate reabsorption | Renal hypouricemia and hyperuricemia models |
| GLUT9/SLC2A9 variants | Altered urate transport | Gout and urate nephrolithiasis models |
| ABCG2 variants | Altered intestinal urate excretion | Hyperuricemia and gout models |
| Uricase (urate oxidase) | Enzymatic urate breakdown in non-human species | Comparative models of urate catabolism |
| Gut microbiome taxa | Microbial urate degradation and metabolome modulation | Sulforaphane and diet intervention studies |
| Inflammatory mediators (IL-1beta, NLRP3) | Response to urate crystals in gout | Gout inflammation models |
| Renal tubular transporters (SLC family) | Urate reabsorption and secretion | CRISPR knockout validation of urate flux |
How Is urate catabolic process Regulated?
Urate catabolic process is regulated at multiple levels. Transcriptional and post-translational regulation of urate transporters such as URAT1, GLUT9 and ABCG2 controls renal and intestinal urate flux. PDZK1 scaffolds these transporters and modulates their activity. Hormonal and metabolic factors, including insulin and dietary components, influence urate reabsorption, and gut microbiome composition can alter urate degradation. Pharmacological inhibition of xanthine oxidase reduces urate production, indirectly regulating the process.
urate catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC22A12 (URAT1) | Renal hypouricemia, hyperuricemia | Knockout HEK293 or renal tubular cell line; point-mutation knock-in |
| SLC2A9 (GLUT9) | Gout, urate nephrolithiasis | Knockout hepatocyte or kidney organoid; overexpression |
| ABCG2 | Hyperuricemia, gout | Intestinal epithelial knockout; tagged knock-in for localization |
| XDH | Hyperuricemia, gout | Knockout hepatocyte model for urate production |
| Gut microbiome | Hyperuricemia progression | Conventionalization or gnotobiotic models with sulforaphane |
Hyperuricemia and gout
Hyperuricemia results from increased urate production or decreased urate excretion, and it is the primary risk factor for gout. Decreased extra-renal urate excretion is a common cause of hyperuricemia, and genetic variants in ABCG2, SLC2A9 and SLC22A12 contribute to gout susceptibility. Urate crystal deposition triggers NLRP3 inflammasome activation and IL-1beta release, causing acute gouty arthritis.
Renal hypouricemia and urate nephrolithiasis
Loss-of-function mutations in URAT1 (SLC22A12) cause renal hypouricemia, characterized by excessive urate excretion and a risk of exercise-induced acute kidney injury. Conversely, urate underexcretion promotes uric acid nephrolithiasis and chronic kidney disease.
Metabolic and cardiovascular associations
Hyperuricemia is associated with metabolic syndrome, hypertension and cardiovascular disease, although causality remains debated. The treatment of hyperuricemia is therefore considered in broader cardiometabolic risk management.
Microbiome and dietary modulation
Sulforaphane-driven reprogramming of the gut microbiome and metabolome ameliorates hyperuricemia progression, suggesting that microbial urate catabolism can be therapeutically targeted. Dietary purine restriction and urate-lowering drugs remain standard approaches.
From urate catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of URAT1 alter urate reabsorption? | SLC22A12 knockout renal epithelial cells |
| Does a gout-associated ABCG2 variant reduce urate efflux? | ABCG2 point-mutation knock-in intestinal cells |
| Can GLUT9 overexpression increase urate transport? | SLC2A9 overexpression in HEK293 or hepatocytes |
| Where is URAT1 localized in polarized cells? | Tagged knock-in of SLC22A12 with fluorescent tag |
| Does xanthine oxidase inhibition lower urate production? | XDH knockout or inhibitor-treated hepatocytes |
| Does microbiome modulation affect urate catabolism? | Gut microbial community knockout or gnotobiotic models |
How to Study the urate catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzymatic urate assay | Urate concentration | Serum, urine or media urate quantification |
| Radiolabeled urate flux | Transport rate | URAT1, GLUT9, ABCG2 functional assays |
| CRISPR knockout screen | Gene requirement for urate handling | Discovery of novel urate regulators |
| RNA-seq | Transcriptional changes | Response to urate or hyperuricemia models |
| 16S rRNA sequencing | Microbial community composition | Gut microbiome-urate interaction |
| Metabolomics | Small-molecule profiles | Sulforaphane or diet intervention |
| Immunofluorescence | Protein localization | Polarized expression of urate transporters |
| Western blot | Protein expression levels | Validation of knockout or overexpression |
Urate quantification assays
Enzymatic and colorimetric urate assays measure urate concentrations in cell culture media, serum or urine to assess net urate catabolic process and transport activity.
Transport flux assays
Radiolabeled or fluorescent urate uptake and efflux assays in polarized cells expressing URAT1, GLUT9 or ABCG2 quantify transport kinetics and the effect of mutations.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that regulate urate sensitivity or transport, while candidate-based knockout validates specific transporters.
Microbiome and metabolome profiling
16S rRNA sequencing and untargeted metabolomics reveal microbial taxa and metabolites associated with urate catabolic process, as shown in sulforaphane intervention studies.
How CRISPR Can Be Used to Study GO:0019628 urate catabolic process
Knockout
CRISPR knockout of SLC22A12, SLC2A9, ABCG2 or XDH in renal, intestinal or hepatic cell lines can determine whether the gene is required for urate reabsorption, efflux or production.
Point Mutation
Introducing gout-associated point mutations in ABCG2 or SLC2A9 by CRISPR base editing or homology-directed repair allows testing of variant-specific effects on urate transport.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous SLC22A12 or SLC2A9 loci enables live-cell imaging and localization studies of urate transporters.
Overexpression
CRISPR activation or lentiviral overexpression of urate transporters and metabolic enzymes can model increased urate catabolic flux and test drug responses.
How EDITGENE Supports urate catabolic process Research
Researchers studying urate catabolic process-related genes often need to determine whether a candidate gene is causally involved in urate transport, production or breakdown. EDITGENE provides CRISPR-based cell model services that enable functional validation of urate transporters and metabolic enzymes in relevant human cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for urate catabolic process research.
Frequently Asked Questions About urate catabolic process
What is urate catabolic process (GO:0019628)?
It is the biological process defined as the chemical reactions and pathways resulting in the breakdown of urate, the anion of uric acid, 2,6,8-trioxypurine.
What genes are involved in urate catabolic process?
Key genes include SLC22A12 (URAT1), SLC2A9 (GLUT9), ABCG2, SLC22A6 (OAT1), SLC22A8 (OAT3) and XDH, which regulate urate transport and production.
Why do humans have urate instead of allantoin?
Humans and great apes have a non-functional uricase gene, so urate is the end product of purine metabolism rather than being further oxidized to allantoin.
How is urate catabolic process related to gout?
Impaired urate excretion or increased production leads to hyperuricemia, which promotes urate crystal deposition and gout.
What is the role of URAT1 in urate catabolic process?
URAT1 (SLC22A12) mediates apical urate reabsorption in the kidney, and its loss causes renal hypouricemia.
How does ABCG2 affect urate levels?
ABCG2 is an ATP-binding cassette transporter that mediates intestinal and renal urate efflux, and its variants are associated with gout.
Can diet or microbiome change urate catabolic process?
Yes, sulforaphane-driven reprogramming of the gut microbiome and metabolome ameliorates hyperuricemia progression in experimental models.
What drugs target urate catabolic process?
Xanthine oxidase inhibitors reduce urate production, while uricosuric agents increase renal urate excretion.
How can CRISPR be used to study urate catabolic process?
CRISPR knockout, point-mutation, knock-in and overexpression models can test causal roles of urate transporters and enzymes in urate handling.
What diseases are linked to defects in urate catabolic process?
Hyperuricemia, gout, renal hypouricemia and uric acid nephrolithiasis are the main associated diseases.
Conclusion
GO:0019628 urate catabolic process is a clinically important biological process because urate is the terminal purine metabolite in humans and its accumulation drives hyperuricemia and gout. Renal and extra-renal urate transporters, together with xanthine oxidase and microbial metabolism, determine net urate balance. CRISPR-based cell models provide a rigorous way to test causal roles of these genes and to accelerate therapeutic development for urate-related diseases.
References
- 1. So A et al.. 2010. Uric acid transport and disease.. J Clin Invest 120(6):1791-9 PMID: 20516647
- 2. Wang R et al.. 2023. Sulforaphane-driven reprogramming of gut microbiome and metabolome ameliorates the progression of hyperuricemia.. J Adv Res 52:19-28 PMID: 36371056
- 3. Mount DB et al.. 2006. Renal urate transport.. Rheum Dis Clin North Am 32(2):313-31, vi PMID: 16716882
- 4. Ichida K et al.. 2012. Decreased extra-renal urate excretion is a common cause of hyperuricemia.. Nat Commun 3:764 PMID: 22473008
- 5. Hisatome I et al.. 1996. [Renal hypouricemia].. Nihon Rinsho 54(12):3337-42 PMID: 8976116
- 6. Anzai N et al.. 2011. Urate transporters: an evolving field.. Semin Nephrol 31(5):400-9 PMID: 22000646
- 7. Gliozzi M et al.. 2016. The treatment of hyperuricemia.. Int J Cardiol 213:23-7 PMID: 26320372
- 8. Merriman TR et al.. 2014. The genetic basis of gout.. Rheum Dis Clin North Am 40(2):279-90 PMID: 24703347
